Debt-to-equity of Moleculin Biotech, Inc. from 30 Sep 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Moleculin Biotech, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2016 to 30 Sep 2025.
  • Moleculin Biotech, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -1551%, a 3283% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Moleculin Biotech, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -1551% -1600% -3283% 30 Sep 2025
Q2 2025 139% +109% +357% 30 Jun 2025
Q1 2025 59% +35% +139% 31 Mar 2025
Q4 2024 53% +34% +181% 31 Dec 2024
Q3 2024 49% +36% +287% 30 Sep 2024
Q2 2024 30% +18% +145% 30 Jun 2024
Q1 2024 25% +14% +126% 31 Mar 2024
Q4 2023 19% +8.8% +87% 31 Dec 2023
Q3 2023 13% +3.5% +39% 30 Sep 2023
Q2 2023 12% +3.9% +45% 30 Jun 2023
Q1 2023 11% +2.3% +27% 31 Mar 2023
Q4 2022 10% +0.31% +3.2% 31 Dec 2022
Q3 2022 9.1% -5.2% -36% 30 Sep 2022
Q2 2022 8.5% -13% -60% 30 Jun 2022
Q1 2022 8.7% -29% -77% 31 Mar 2022
Q4 2021 9.8% -69% -88% 31 Dec 2021
Q3 2021 14% -65% -82% 30 Sep 2021
Q2 2021 21% -50% -70% 30 Jun 2021
Q1 2021 37% -20% -34% 31 Mar 2021
Q4 2020 79% +26% +50% 31 Dec 2020
Q3 2020 79% +32% +67% 30 Sep 2020
Q2 2020 72% +30% +72% 30 Jun 2020
Q1 2020 57% +16% +37% 31 Mar 2020
Q4 2019 53% +18% +53% 31 Dec 2019
Q3 2019 47% +19% +64% 30 Sep 2019
Q2 2019 42% +20% +91% 30 Jun 2019
Q1 2019 42% +27% +194% 31 Mar 2019
Q4 2018 34% +20% +133% 31 Dec 2018
Q3 2018 29% +15% +108% 30 Sep 2018
Q2 2018 22% +8.5% +64% 30 Jun 2018
Q1 2018 14% +1.5% +12% 31 Mar 2018
Q4 2017 15% +4.4% +42% 31 Dec 2017
Q3 2017 14% +0.45% +3.4% 30 Sep 2017
Q2 2017 13% 30 Jun 2017
Q1 2017 13% 31 Mar 2017
Q4 2016 10% 31 Dec 2016
Q3 2016 13% 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.